Ann: Appendix 4C - quarterly, page-83

Hello all,

Very happy with today's 4c announcement and results. I think we are entering a major growth phase for CardioCel sales over the next 12 months.  Enough blabbing from me...here are my updated graphs.


Number of Surgeries  - I think these next two graphs speaks for themselves on the uptake of CardioCel by surgeons  in the previous quarter.  Are we finally seeing exponential growth occurring in CardioCel sales ?





Revenue and costs.  Staff costs has increased (as you would expect from a company in a growth phase) but the gap appears to be closing between staff costs and Customer Receipts.



No updates on the number of centres world wide or within regions  in today's announcement but here are my latest graphs on those figures anyway.






Catalysts ahead for CardioCel are: (taken from Proactive Investors)

- Growing number of global heart centres using CardioCel to repair heart defects including repairing heart valves;
- Additional regulatory approvals in Asia for CardioCel;
- Initiation of an aortic valve repair study to show CardioCel’s utility and advantages in aortic repair vs aortic valve replacement (aortic valve market today is large and mostly using replacement procedures as they haven’t had suitable tissue to repair); and
- Expanded ADAPT pipeline in areas such as vessel repairs, cellular therapies and progressing our dura mater product towards studies for market approvals.

In addition, the company expects that its therapeutic vaccine Phase II study for Herpes Simplex 2 (HSV-2) will complete enrolment in the near future with interim results reported by the end of this calendar year.  

This vaccine is led by Professor Ian Frazer and represents a large target market, making it an inflection point this year.

In addition, Admedus is progressing Ian Frazer’s next HPV vaccine into clinical study this financial year.  This vaccine is being developed as a treatment against HPV and cervical cancer.


Finally I thought I would throw candle chart of the SP. Looks like that trend  heading upwards is on track to continue.  Less volume today on news compared to what we have recently seen.



Looking forward to the SP action over the next few trading days.

As always - Do your own research.

Haplo